10x Genomics
330 hedge funds and large institutions have $11.5B invested in 10x Genomics in 2021 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 117 increasing their positions, 105 reducing their positions, and 51 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 105
2.16% less ownership
Funds ownership: 89.13% → 86.97% (-2.2%)
3% less funds holding
Funds holding: 340 → 330 (-10)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
14% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 51
25% less capital invested
Capital invested by funds: $15.2B → $11.5B (-$3.76B)
57% less call options, than puts
Call options by funds: $32.4M | Put options by funds: $75.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$300M |
| 2 |
BlackRock
New York
|
+$138M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$87.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$80.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$206M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$113M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$77.2M |
| 4 |
Goldman Sachs
New York
|
-$54.5M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$53M |
TXG Hedge Fund Activity: Q3 2021 in Review
330 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2021, worth a combined $11.5B — down 25% from $15.2B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of TXG and 44 opened new positions — a net loss of 7 holders — while 105 trimmed existing stakes and 117 added.
The largest buyer was Morgan Stanley, adding an estimated $300M. The largest seller was ARK Investment Management, cutting an estimated $206M.
- 330 institutional investors held 10x Genomics (TXG) as of Q3 2021, down from 340 in Q2 2021.
- Funds reported $11.5B of 10x Genomics stock for Q3 2021, down 25% quarter-over-quarter.
- 44 funds opened new 10x Genomics positions in Q3 2021 and 51 closed out, a net change of -7 holders.
- The largest 10x Genomics buyer in Q3 2021 was Morgan Stanley, an estimated $300M added.
- The largest 10x Genomics seller in Q3 2021 was ARK Investment Management, an estimated $206M sold.
Based on aggregated 13F filings for Q3 2021.